ONCY pelareorep demonstrates 69% ORR in pancreatic cancerONCY pelareorep biomarker data in pancreatic cancer
"Using patient blood samples from our REO 024 study in second line pancreatic cancer, T cell receptor sequencing was performed with Adaptive Biotechnologies' immunoSEQ Assay to measure the diversity or clonality of the T cell population,'' said Dr. Rita Laeufle, CMO of Oncolytics Biotech. ''Results from this analysis demonstrate that higher clonality after one three-week cycle of treatment can identify patients likely to respond to combination treatment of pelareorep and a checkpoint inhibitor.''
https://www.accesswire.com/537346/Oncolytics-BiotechR-Presents-Biomarker-Data-in-Second-line-Pancreatic-Cancer-at-AACR